Search clinical trials for: CYP3A4 inhibitor
Total 67815 results
-
Karolinska University HospitalAstraZenecaCompleted
-
University of Michigan Rogel Cancer CenterWithdrawn
-
PfizerCompletedPharmacokinetics | Cytochrome P-450 CYP2D6 | CYP3A4 Protein, HumanUnited States
-
University Hospital, GenevaCompletedAnticoagulants and Bleeding DisordersSwitzerland
-
Jazz PharmaceuticalsCompletedEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19...United Kingdom
-
Zhujiang HospitalCompletedChronic Obstructive Pulmonary Disease | AsthmaChina
-
Natalia Valadares de MoraesUniversity of Sao Paulo; Fundação de Amparo à Pesquisa do Estado de São PauloEnrolling by invitationObesity | Bariatric Surgery | Roux-en Y Gastric BypassUnited States
-
Toray Industries, IncCompleted
-
GlaxoSmithKlineCompletedAtherosclerosisUnited States
-
GlaxoSmithKlineCompleted
-
Genelex CorporationUniversity of UtahCompletedDrug Interaction Potentiation | Adverse Drug Events | Adverse Drug Reactions | Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant | Drug Metabolism, Poor, CYP2D6-RELATED | Drug Metabolism, Poor, CYP2C19-RELATED | Cytochrome P450 Enzyme Deficiency | Cytochrome P450 CYP2D6 Enzyme Deficiency | Cytochrome... and other conditionsUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Drug-Drug Interaction (DDI) | Pharmacokinetics of EnzalutamideGermany
-
University of Southern DenmarkOdense University HospitalCompleted
-
University Hospital Bispebjerg and FrederiksbergCompletedAlcohol WithdrawalDenmark
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompleted
-
Theravance BiopharmaCompleted
-
University of WashingtonNational Institute of General Medical Sciences (NIGMS)CompletedHealthy Volunteers | Drug-Drug Interaction
-
Vantia LtdCompleted
-
Janssen Research & Development, LLCCompletedHealthy ParticipantsUnited States
-
Janssen Research & Development, LLCCompleted
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
-
Jill M KolesarNational Cancer Institute (NCI); NovartisRecruitingMetastatic Melanoma | BRAF Gene MutationUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedHealthy VolunteersUnited States
-
University of WashingtonNational Institute of General Medical Sciences (NIGMS)Completed
-
Bristol-Myers SquibbCompletedHealthy ParticipantsUnited States
-
CelgeneImpact Biomedicines, Inc., a wholly owned subsidiary of Celgene CorporationCompleted
-
Helwan UniversityAin Shams UniversityCompletedRenal TransplantationEgypt
-
Eisai Inc.Completed
-
PfizerCompleted
-
Chong Kun Dang PharmaceuticalCompleted
-
Shirley M. TsunodaUnknownKidney Transplant; Complications | Drug Interaction Food
-
Children's Mercy Hospital Kansas CityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Huazhong University of Science and TechnologyCompleted
-
Bristol-Myers SquibbRecruitingHealthy ParticipantsUnited States
-
Radboud University Medical CenterCompletedTesticular CancerNetherlands
-
Lawson Health Research InstituteCompleted
-
Odense University HospitalNovartis; Danish Research AgencyCompletedMetabolic Clearance RateDenmark
-
The Netherlands Cancer InstituteCompletedProstate Cancer | Solid Tumor, AdultNetherlands
-
Genelex CorporationCompletedDrug Metabolism, Poor, CYP2D6-RELATED | Drug Metabolism, Poor, CYP2C19-RELATED | Cytochrome P450 CYP2D6 Enzyme Deficiency | Cytochrome P450 CYP2C9 Enzyme Deficiency | Cytochrome P450 CYP2C19 Enzyme Deficiency | Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant | CYP2D6 Polymorphism | Ultrarapid... and other conditionsUnited States
-
Janssen Research & Development, LLCCompleted
-
National Institutes of Health Clinical Center (CC)Completed
-
Chiesi Farmaceutici S.p.A.RecruitingChronic Obstructive Pulmonary DiseaseBulgaria
-
Genelex CorporationHarding UniversityCompletedDrug Interaction Potentiation | Adverse Drug Events | Adverse Drug Reactions | Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant | Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant | Drug Metabolism, Poor, CYP2D6-RELATED | Drug Metabolism, Poor, CYP2C19-RELATED | Cytochrome P450 Enzyme... and other conditionsUnited States
-
Millennium Pharmaceuticals, Inc.Completed
-
PfizerCompletedHealthy ParticipantBelgium
-
Vanda PharmaceuticalsCompleted
-
PfizerCompletedHealthy ParticipantUnited States
-
PfizerCompleted
-
Xianwei ZhangCompletedSurgery | IndividualityChina